These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 37316750)
1. Real-World, Retrospective, Multicenter, Observational Study on the Use of the First Liquid AbobotulinumtoxinA in Italy. Di Gregorio C; Tretti-Clementoni M; Belmontesi M; Romagnoli M; Innocenti A; Zanchi M; Leone L; Damiani G; Iozzo I Dermatol Ther (Heidelb); 2023 Jul; 13(7):1603-1610. PubMed ID: 37316750 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of AbobotulinumtoxinA for the Treatment of Glabellar Lines in Chinese Patients: A Pivotal, Phase 3, Randomized, Double-Blind and Open-Label Phase Study. Wu Y; Fang F; Lai W; Li C; Li L; Liu Q; Lu J; Pang X; Sun J; Shi X; Picaut P; Prygova I; Andriopoulos B; Sun Q Aesthetic Plast Surg; 2023 Feb; 47(1):351-364. PubMed ID: 36536093 [TBL] [Abstract][Full Text] [Related]
3. Long-term Efficacy and Safety of Liquid AbobotulinumtoxinA Formulation for Moderate-to-Severe Glabellar Lines: A Phase III, Double-Blind, Randomized, Placebo-Controlled and Open-Label Study. Kestemont P; Hilton S; Andriopoulos B; Prygova I; Thompson C; Volteau M; Ascher B Aesthet Surg J; 2022 Feb; 42(3):301-313. PubMed ID: 34472596 [TBL] [Abstract][Full Text] [Related]
4. Patient Satisfaction with AbobotulinumtoxinA for Aesthetic Use in the Upper Face: A Systematic Literature Review and Smit R; Gubanova E; Kaufman J; Landau M; Molina B; Andriopoulos B; Maisonobe P; Prygova I; Redaelli A J Clin Aesthet Dermatol; 2021 Feb; 14(2):E69-E88. PubMed ID: 34221231 [No Abstract] [Full Text] [Related]
5. Pain Reduction With AbobotulinumtoxinA for the Treatment of Hallux Valgus in Adult Participants: Results of a Randomized and Placebo-Controlled Phase 2 Trial. Armstrong DG; DiDomenico LA; Baravarian B; Parekh SG; Volteau M; Silva R J Foot Ankle Surg; 2023; 62(2):244-253. PubMed ID: 36335048 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of abobotulinumtoxinA versus onabotulinumtoxinA for the treatment of refractory neurogenic detrusor overactivity: a systematic review and indirect treatment comparison. Cruz F; Danchenko N; Fahrbach K; Freitag A; Tarpey J; Whalen J J Med Econ; 2023; 26(1):200-207. PubMed ID: 36647624 [TBL] [Abstract][Full Text] [Related]
7. Sustained functional benefits after a single set of injections with abobotulinumtoxinA using a 2-mL injection volume in adults with cervical dystonia: 12-week results from a randomized, double-blind, placebo-controlled phase 3b study. Patel AT; Lew MF; Dashtipour K; Isaacson S; Hauser RA; Ondo W; Maisonobe P; Wietek S; Rubin B; Brashear A PLoS One; 2021; 16(2):e0245827. PubMed ID: 33524060 [TBL] [Abstract][Full Text] [Related]
8. Liquid Formulation of AbobotulinumtoxinA Exhibits a Favorable Efficacy and Safety Profile in Moderate to Severe Glabellar Lines: A Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Trial. Ascher B; Kestemont P; Boineau D; Bodokh I; Stein A; Heckmann M; Dendorfer M; Pavicic T; Volteau M; Tse A; Picaut P; Rzany B Aesthet Surg J; 2018 Feb; 38(2):183-191. PubMed ID: 28200002 [TBL] [Abstract][Full Text] [Related]
9. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557 [TBL] [Abstract][Full Text] [Related]
10. The cost-effectiveness of abobotulinumtoxinA (Dysport) and onabotulinumtoxinA (Botox) for managing spasticity of the upper and lower limbs, and cervical dystonia. Danchenko N; Johnston KM; Whalen J J Med Econ; 2022; 25(1):919-929. PubMed ID: 35730362 [TBL] [Abstract][Full Text] [Related]
11. Real-world effectiveness of abobotulinumtoxinA (Dysport®) in adults with upper limb spasticity in routine clinical practice: an observational study. Sarzyńska-Długosz I; Szczepańska-Szerej A; Drużdż A; Łukomski T; Ochudło S; Fabian A; Sobolewski P; Mariańska K; Maciejewska J; Mulek E; Niedzielska A; Raymond R; Brzózka MM; Jessa-Jabłońska M Neurol Neurochir Pol; 2020; 54(1):90-99. PubMed ID: 31956971 [TBL] [Abstract][Full Text] [Related]
12. Comparison of Effectiveness and Safety of a Botulinum Toxin Monotherapy and a Combination Therapy with Hyaluronic Acid Filler for Improving Glabellar Frown. Kim JH; Park ES; Nam SM; Choi CY Aesthetic Plast Surg; 2022 Aug; 46(4):1872-1880. PubMed ID: 35552477 [TBL] [Abstract][Full Text] [Related]
13. AbobotulinumtoxinA Treatment of Glabellar Lines Using a New Reconstitution and Injection Volume: Randomized, Placebo-Controlled Data. Schlessinger J; Friedmann DP; Mayoral F; Mraz Robinson D; Glaser D; Wu D; Marcus K; Somenek M; Lin X J Drugs Dermatol; 2021 Sep; 20(9):988-995. PubMed ID: 34491022 [TBL] [Abstract][Full Text] [Related]
14. Treatment of forehead/glabellar rhytide complex with combination botulinum toxin a and hyaluronic acid versus botulinum toxin A injection alone: a split-face, rater-blinded, randomized control trial. Dubina M; Tung R; Bolotin D; Mahoney AM; Tayebi B; Sato M; Mulinari-Brenner F; Jones T; West DP; Poon E; Nodzenski M; Alam M J Cosmet Dermatol; 2013 Dec; 12(4):261-6. PubMed ID: 24305424 [TBL] [Abstract][Full Text] [Related]
15. An analysis of efficacy data from four phase III studies of botulinum neurotoxin type A-ABO for the treatment of glabellar lines. Baumann L; Brandt FS; Kane MA; Donofrio LM Aesthet Surg J; 2009 Nov; 29(6 Suppl):S57-65. PubMed ID: 19945006 [TBL] [Abstract][Full Text] [Related]
16. Comparative evaluation of the safety and efficacy of botulinum toxin type A and topical creams for treating moderate-to-severe glabellar rhytids. Beer KR Dermatol Surg; 2006 Feb; 32(2):184-97. PubMed ID: 16442037 [TBL] [Abstract][Full Text] [Related]
17. Remodeling of periorbital, temporal, glabellar, and crow's feet areas with hyaluronic acid and botulinum toxin. Beer KR; Julius H; Dunn M; Wilson F J Cosmet Dermatol; 2014 Jun; 13(2):143-50. PubMed ID: 24910278 [TBL] [Abstract][Full Text] [Related]
18. Liquid AbobotulinumtoxinA: Pooled Data From Two Double-Blind, Randomized, Placebo-Controlled Phase III Studies of Glabellar Line Treatment. Hilton S; Kestemont P; Sattler G; Volteau M; Thompson C; Andriopoulos B; Prygova I; Berg AK; Ascher B Dermatol Surg; 2022 Nov; 48(11):1198-1202. PubMed ID: 36206385 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of AbobotulinumtoxinA in Patients with Neurogenic Detrusor Overactivity Incontinence Performing Regular Clean Intermittent Catheterization: Pooled Results from Two Phase 3 Randomized Studies (CONTENT1 and CONTENT2). Kennelly M; Cruz F; Herschorn S; Abrams P; Onem K; Solomonov VK; Del Rosario Figueroa Coz E; Manu-Marin A; Giannantoni A; Thompson C; Vilain C; Volteau M; Denys P; Eur Urol; 2022 Aug; 82(2):223-232. PubMed ID: 35400537 [TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of 3- and 5-injection patterns (30 and 50 U) of botulinum toxin A (Dysport) for the treatment of wrinkles in the glabella and the central forehead region. Rzany B; Ascher B; Fratila A; Monheit GD; Talarico S; Sterry W Arch Dermatol; 2006 Mar; 142(3):320-6. PubMed ID: 16549707 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]